Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comorbidity Phenotype Trajectories in Veterans Before and After Emergence of Epilepsy
Neuroepidemiology
S12 - Neuroepidemiology (2:12 PM-2:24 PM)
007

Comorbidities common in epilepsy are burdensome to patients and may also be associated with mortality. However, little is known about how phenotypic patterns of comorbidity before and after emergence of epilepsy, and their associations with mortality/cause of death. 

Identify phenotypic patterns of comorbidity in epilepsy.

We identified epilepsy and seizure index date in a cohort of Post-9/11 Era Veterans in VA care (2002-2018). We included those with data available for a 5 year ‘trajectory’ period centered on the index date (-2, index [0], +2 years). For each year we identified diagnoses for 26 conditions associated with traumatic brain injury (TBI), post-concussion symptoms, chronic disease, and mental health conditions. Latent class analysis (LCA) grouped Veterans based on similarity of comorbidity trajectories (phenotypes) over the 5-year period, and examined mortality and cause of death associated with phenotypes adjusted for demographic characteristics. 

15,716 Veterans met inclusion criteria (mean age 33.5; SD 9.9). LCA identified 6 phenotypes. 

Healthy: few comorbidities except brain tumor (highest in this group). 

Deterioration: moderate probabilities of mental health conditions that increased over time. 

Bipolar/Substance Use Disorder (SUD)

 Chronic Disease: hypertension, cerebrovascular disease (CVD), cardiac disease

Post-traumatic Stress Disorder (PTSD): PTSD, TBI, headache 

Polytrauma: TBI, PTSD, pain. headache, lung disease 

All-cause mortality was significantly higher for Chronic Disease and Bipolar/SUD groups (p<.01). Cause of death also varied by phenotype.  Death by Accident/suicide was significantly higher in PTSD, Bipolar/SUD, and Deterioration groups. Cancer death was significantly higher in the Healthy group. CVD death was significantly higher in Chronic Disease (p<.01).

Treating the seizure is not the sum total of treating the patient with epilepsy. We identified six epilepsy comorbidity phenotypes, which were associated with mortality and cause of death. Future work will identify optimal treatment approaches and develop risk scores to identify early, individuals that are likely to have adverse outcomes.

Authors/Disclosures
Mary Jo Pugh, PhD, RN, FAAN
PRESENTER
The institution of Dr. Pugh has received research support from Department of Defense, Epilepsy Research Program. The institution of Dr. Pugh has received research support from VA Health Services Research and Development Service. The institution of Dr. Pugh has received research support from VA Rehabilitation Research and Development Service. The institution of Dr. Pugh has received research support from Congressionally Directed Research Programs. The institution of Dr. Pugh has received research support from Sanofi.
W. C. LaFrance, Jr., MD, MPH, FAAN (Rhode Island Hospital) Dr. LaFrance has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for medico-legal work.. The institution of Dr. LaFrance has received research support from Department of Defense. Dr. LaFrance has received publishing royalties from a publication relating to health care. Dr. LaFrance has received publishing royalties from a publication relating to health care.
Sidney Hinds, MD, FAAN (SCS Consulting, LLC) An immediate family member of Dr. Hinds has received personal compensation for serving as an employee of Henry Jackson Foundation. Dr. Hinds has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otolith. Dr. Hinds has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ICON. Dr. Hinds has received personal compensation in the range of $500-$4,999 for serving as a Consultant for The Conafay Group. Dr. Hinds has received research support from Uniformed Service University. Dr. Hinds has received personal compensation in the range of $500-$4,999 for serving as a Panel member with Congressionally Directed Medical Research Program. Dr. Hinds has a non-compensated relationship as a Ex Offcio Board member with NINDS/NANDS that is relevant to AAN interests or activities.
Alan R. Towne, MD, MPH (Virginia Commonwealth Univ/Richmond VA Medical Center) The institution of Dr. Towne has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Towne has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Towne has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. Dr. Towne has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Towne has received research support from DOD.
Anne C. Van Cott, MD, FAAN (VA Pittsburgh Healthcare System/University of Pittsburgh) Dr. Van Cott has nothing to disclose.
Christine B. Baca, MD, FAAN (Virginia Commonwealth University) Dr. Baca has nothing to disclose.
Hamada H. Altalib, DO (VA Connecticut Healthcare System) The institution of Dr. Altalib has received research support from UCB. The institution of Dr. Altalib has received research support from Eisai. The institution of Dr. Altalib has received research support from Sunovian. The institution of Dr. Altalib has received research support from DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS.
No disclosure on file